CompletedPhase 1

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Asset

LY4086940

Oral / Intravenous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

Actual enrollment

219

Study population

Healthy volunteers, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 22-35•HbA1c 6.5-10.5%•Healthy volunteers

Primary endpoint

•One or More Serious Adverse Events (SAE) Considered by the Investigator to be

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06945419

Org study ID27267

Secondary IDJ5U-MC-YGAAEli Lilly and Company

Timeline

Milestones

Study start2025-04-23actual

Study first posted2025-04-25actual

Primary completion2026-08-05actual

Study completion2026-08-05actual

Last update posted2026-08-19actual

Assets

Investigational agents

LY4086940

Who this study enrolls

Healthy volunteersObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Have no significant body weight change for the 3 months prior to screening

Part A and Part E:

•Are considered healthy

•Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening

Part B:

•Have a BMI of 27 to 45 kg/m2 at screening

Part C:

•Have a BMI of 25 to 45 kg/m2 at screening

Part D:

•Have type 2 diabetes

•Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening

•Have a BMI of 27 to 45 kg/m2 at screening

Exclusion criteria

•Have had an acute cardiovascular condition within the past 6 months prior to screening

•Have liver disease or pancreatitis

•Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C, E:

•Have any form of diabetes

Part D:

•Have type 1 diabetes

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline up to Week 9

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4086940

Time frame:Predose up to Day 64

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve (AUC) of LY4086940

Time frame:Predose up to Day 64

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.